Most important papers as first author
| 1986 | K. H. Link et al.: Prospective correlative chemosensitivity testing in high dose intraarterial chemotherapy for liver metastases. Cancer Research 46, 4837-4840 |
| 1988 | K. H. Link et al.: Concentration and time dependance of the toxicity of fluorinated pyrimidines to HT29 colorectal carcinoma cells. Cancer Chemotherapy and Pharmacology 22, 58-62 |
| 1995 | K. H. Link et al.: Rationales for intraperitoneal chemotherapy: Chemosensitivity Testing and Pharmacokinetic Considerations – Clinical Experience with Intraperitoneal Chemotherapy. Acta Chirurgica Austriaca 27, 95-100 |
| 1996 | K. H. Link et al.: Regional Chemotherapy Directed by Individual Chemosensitivity Testing in Vitro: A Prospective Decision-Aiding Trial. Clinical Cancer Research 3, 1469-1474 |
| 1997 | K. H. Link et al.: Multimodal Therapies in Ductal Pancreatic Cancer. Int.J.Pancreatol. 21, 71-83 |
| 1999 | K. H. Link et al.: Downstaging by regional chemotherapy of nonresectable isolated colorectal liver metastases. Eur J Surg Oncol 25, 381-388 |
| 2000 | K. H. Link et al.: Thymidilate synthase quantitation and in vitro chemosnesitivity testing predicts responses and survival of patients with isolated non-resectable liver tumors receiving hepatic arterial infusion. Cancer 89, 288-296 Bemerkung: Ausgezeichnet als “Best Paper of the Year” |
| 2000 | K. H. Link et al.: Neue Prinzipien in der Chirurgischen Onkologie. Onkologe 6, 450-457 |
| 2001 | K. H. Link et al.: Surgery, Radio- and Chemotherapy for Multimodal Treatment of Rectal Cancer. Swiss Surg 7, 256-274 |
| 2001 | K. H. Link et al.: Regional Chemotherapy of Nonresectable Colorectal Liver Metastases with Mitoxantrone, 5-Fluorouracil, Folinic Acid, and Mitomycin C May Prolong Survival. Cancer 92, 2746-53 |
| 2001 | K. H. Link: Wandel der Therapie beim resektablen Rektumkarzinom. Internist 42, 910-912 |
| 2004 | K. H. Link et al.: Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidenzbasis? Chir Gastroenterologie 20, 39-54 |
| 2004 | K. H. Link et al.: Multimodality Treatment of Hepatic Metastases. In: Lencioni et al., Springer, 363-386 |
| 2005 | K. H. Link et al.: Increase of Survival Benefit in Advanced Resectable Colon Cancer by Extent of Adjuvant Treatment. Annals of Surgery 242, 178-187 |
| 2005 | K. H. Link et al.: Colon cancer: survival after curative surgery. Langenbeck´s Arch Surg 390, 83-93 |
| 2008 | K. H. Link, M. Hauser, M. Mann, P. M. Schlag: Kolonkarzinom – Chirurgische Onkologie Strategien und Standards für die Praxis. Michael Gnant, Peter M. Schlag (Hrsg.), Springer, 315-329 |
| 2009 | K. H. Link et al.: Multimodale Therapie von Kolon- und Rektumkarzinomen: Qualitätsparameter. Viszeralmedizin 25, 105-117 |
| 2010 | K. H. Link et al.: Qualitätsanforderungen zur Behandlung des Kolon- und Rektumkarzinoms aus chirurgischer Sicht. Chirurg 81, 222-230 |
| 2010 | K. H. Link et al.: Qualitätsanforderungen zur Behandlung des Kolon- und Rektumkarzinoms aus chirurgischer Sicht Chirurg 81, 222-230 |
| 2011 | K. H. Link, H.Hauser, M.Mann, P.M.Schlag: Kolonkarzinom – Die Sicht der Chirurgie. Wiener Klinisches Magazin 14, 3, 22-28. |
| 2012 | Th. Weber, M. Roitman, K. H. Link: Current Status of Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer. Clinical Colorectal Cancer, Vol.11, Nr.3, 167-76. |
Most important papers as co-author
| 1997 | H. G. Beger, M. H.Schoenberg, K. H. Link, F. Safi, D. Berger: Die duodenumerhaltende Pankreaskopfresektion – Ein Standardverfahren bei chronischer Pankreatitis. Chirurg 68, 874-880 |
| 1999 | H. G. Beger, F. Gansauge, M. W. Büchler, K. H. Link: Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction of occurence of liver metastasis . World J Surg 23, 946-949 |
| 2001 | J. P. Neoptolemos, J. A. Dunn, D. D. Stocken, J. Almond, K. H. Link, H..Beger, C. Bassi, M. Falconi, P. Pederzoli, C. Dervenis, L. Fernandez-Cruz, F. Lacaine, A. Pap, D. Spooner, D. J. Kerr, H. Friess, M.W. Büchler for the European Study Group for Pancreatic Cancer: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. The Lancet 358, 1576-85 |
| 2002 | L. Staib, K. H. Link, A. Blatz, H.G. Beger: Surgery of Colorectal Cancer: Surgical Morbidity and Five- and Ten-year Results in 2400 Patients. -Monoinstitutional Experience. World J Surg 26, 59-66 |
| 2002 | M. Kornmann, K. H. Link: Conversion of locally inoperable primary rectal cancer with multiple liver metastases to an option for cure after local down-staging and hepatic arterial infusion chemotherapy. Langenbeck´s Arch Surg 387, 90-93 |
| 2003 | B. U. M. Monz, H. H. König, R. Leidl, L. Staib, K. H. Link: Cost Effectiveness of Adding Folinic Acid to Fluorouracil Plus Levamisole as Adjuvant Chemotherapy in Patients with Colon Cancer in Germany. Pharmacoeconomics 21, 709-719 |
| 2003 | M. Kornmann, W. Schwabe, S. Sander, M. Kron, J. Strater, S. Polat, E. Kettner, H. F. Weiser, W. Baumann, H. Schramm, P. Hausler, K. Ott, D. Behnke, L. Staib, H. G. Beger, K. H. Link : Thymidylate Synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Research 9, 4116-24 |
| 2003 | H. G. Beger, B. Rau, F. Gansauge, B. Poch, K. H. Link: Treatment of Pancreatic Cancer: Challenge of the Facts. Editorial Update. World J Surg 27, 1075-1084 |
| 2007 | M. Kornmann, L. Staib, K. H. Link: Aktuelle chirurgische Therapiestrategien – Rektumkarzinom. Verdauungskrankheiten 25, 163-170 |
| 2007 | Th. Weber, K. H. Link: Radikale Chirurgie bei primär metastasierten kolorektalen Karzinomen. Chir Gastroenterol 23, 360-66 |
| 2009 | W. Hohenberger, K. H. Link, J. Spatz, M. Anthuber, U. Widmaier, M. H. Schoenberg: Stellenwert der laparoskopischen operativen Behandlung von Rektumkarzinomen. Chirurgische Praxis 70, 3-9 |
| 2010 | M. Kornmann, L. Staib, T. Wiegel, E. D. Kreuser, M. Kron, W. Baumann, Henne-Bruns, and K. H. Link: Adjuvant radiochemotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon alpha Br J Cancer 103, 1163-1172 |